Apomorphine, a nonselective dopamine receptor agonist, facilitates penile erection and is effective in patients suffering from erectile dysfunction. The specific dopamine receptor subtype(s) responsible for its erectogenic effect is not known. Here we report that the dopamine D4 receptor plays a role in the regulation of penile function. ABT-724 is a selective dopamine D 4 receptor agonist that activates human dopamine D 4 receptors with an EC50 of 12.4 nM and 61% efficacy, with no effect on dopamine D 1, D2, D3, or D5 receptors. ABT-724 dose-dependently facilitates penile erection when given s.c. to conscious rats, an effect that is blocked by haloperidol and clozapine but not by domperidone. A proerectile effect is observed after intracerebroventricular but not intrathecal administration, suggesting a supraspinal site of action. s.c. injections of ABT-724 increase intracavernosal pressure in awake freely moving rats. In the presence of sildenafil, a potentiation of the proerectile effect of ABT-724 is observed in conscious rats. The ability of ABT-724 to facilitate penile erection together with the favorable side-effect profile indicates that ABT-724 could be useful for the treatment of erectile dysfunction. P enile erection is the result of a complex series of integrated neuronal and vascular events that leads to accumulation of blood in the penis to achieve rigidity. The coordination of several neural events is required to release endogenous mediators (i.e., nitric oxide) at the level of the penile smooth muscle to induce relaxation, whereas a disruption of this series of events can lead to erectile dysfunction (ED) (1, 2). Traditionally, drugs used for the treatment of ED have had a peripheral site of action, including phosphodiesterase (PDE)-5 inhibitors like sildenafil, but the recent demonstration that apomorphine can facilitate penile erection in ED patients has introduced a new approach to treatment, because apomorphine acts on central dopaminergic systems (3, 4) . Dopamine is the main catecholamine in the CNS and is involved in a variety of physiological functions, including sexual behavior, cognition, motor coordination, cardiovascular control, reward, hormonal regulation; abnormalities in dopaminergic neurotransmission have been implicated in Parkinson's disease, schizophrenia, attention-deficit disorder, depression, and drug abuse, among other disorders (5, 6). The regional distribution of the receptor subtypes, the recent generation of knock-out animals, and the availability of a large number of dopaminergic agents have aided researchers in clarifying the biological role of the dopamine receptors. Dopamine receptors in mammalian tissues have been classified as D 1 -like (D 1 and D 5 ) and D 2 -like (D 2 , D 3 , and D 4 ) based on their binding properties and their ability to activate or inhibit forskolin-induced adenylate cyclase activity, a classification supported by the cloning of the different subtypes during the last decade (7, 8) .
P
enile erection is the result of a complex series of integrated neuronal and vascular events that leads to accumulation of blood in the penis to achieve rigidity. The coordination of several neural events is required to release endogenous mediators (i.e., nitric oxide) at the level of the penile smooth muscle to induce relaxation, whereas a disruption of this series of events can lead to erectile dysfunction (ED) (1, 2) . Traditionally, drugs used for the treatment of ED have had a peripheral site of action, including phosphodiesterase (PDE)-5 inhibitors like sildenafil, but the recent demonstration that apomorphine can facilitate penile erection in ED patients has introduced a new approach to treatment, because apomorphine acts on central dopaminergic systems (3, 4) . Dopamine is the main catecholamine in the CNS and is involved in a variety of physiological functions, including sexual behavior, cognition, motor coordination, cardiovascular control, reward, hormonal regulation; abnormalities in dopaminergic neurotransmission have been implicated in Parkinson's disease, schizophrenia, attention-deficit disorder, depression, and drug abuse, among other disorders (5, 6) . The regional distribution of the receptor subtypes, the recent generation of knock-out animals, and the availability of a large number of dopaminergic agents have aided researchers in clarifying the biological role of the dopamine receptors. Dopamine receptors in mammalian tissues have been classified as D 1 -like (D 1 and D 5 ) and D 2 -like (D 2 , D 3 , and D 4 ) based on their binding properties and their ability to activate or inhibit forskolin-induced adenylate cyclase activity, a classification supported by the cloning of the different subtypes during the last decade (7, 8) .
Within the D 2 -like family, the D 2 receptor is highly expressed in the caudate, accumbens, cortex, hypothalamus, pituitary gland, and areas where the cell bodies that project to these regions are located, like the ventral tegmental area and the substantial nigra. The systemic administration of dopamine D 2 agonists increases locomotion and modulates prolactin release but, more importantly, the blockade of D 2 receptors in mesocortical and mesolimbic pathways has been associated with the therapeutic effect of antipsychotic drugs (8) . D 3 receptors are highly expressed in the island of Calleja, hypothalamus, and thalamus, and are an attractive target for the potential treatment of drug abuse in view of the inhibition of cocaine-seeking behavior induced by the partial D 3 agonist BP897 (9) . On the other hand, the D 4 receptor is more abundant in the frontal cortex, hippocampus, amygdala, and hypothalamus, but pharmacological studies have failed to reveal any psychopharmacological effect in rats (10) . The therapeutic effect of clozapine in psychotic patients that do not respond to classical antipsychotic agents like haloperidol prompted the hypothesis that D 4 receptors may be responsible for the antipsychotic activity as clozapine is a preferential D 4 antagonist (11) .
With regard to sexual function, a substantial body of experimental data indicates that several central neurotransmitters and neuropeptides are involved in the control of penile erection and sexual behavior, including dopamine (12, 13) . The participation of dopamine is supported by studies demonstrating that several dopamine receptor agonists like apomorphine, quinpirole, quinelorane, and (-)-3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP) induce penile erection after systemic administration in mammals (12) . The proerectile effect of apomorphine exhibits a characteristic inverted-U response and is observed in rats, rabbits, and monkeys (13) (14) (15) . Apomorphine is a potent nonselective dopamine receptor agonist that activates all of the dopamine receptor subtypes (8) , and it has been reported by several laboratories that the proerectile effect of apomorphine is mediated via the D 2 receptor subtype; however, recent studies with selective dopamine agonists did not confirm this hypothesis (16) . The dopamine D 4 receptor is expressed in brain areas like the cortex and hypothalamus, areas that are known to control sexual function in mammals (17) . The role of dopamine D 4 receptors in penile erection was investigated in our laboratory by using ABT-724 (2-[(4-pyridin-2-ylpiperazin-1-yl)methyl]-1H-benzimidazole), a highly selective D 4 agonist that is structurally different from apomorphine. To determine the poten-tial therapeutic use of ABT-724 for the treatment of male ED, the effect on cardiovascular, CNS, and gastrointestinal function was investigated in animal models. Fluorometric Imaging Plate Reader (FLIPR) Assay. Agonist-induced intracellular Ca 2ϩ changes were assessed by using Fluo-4 in conjunction with FLIPR (Molecular Devices). Fluo-4 was dissolved in anhydrous DMSO and diluted in Dulbecco's phosphate buffer saline containing 0.5 M 3-isobutyl-1-methylxanthine and 0.004% ascorbic acid to a final concentration of 2 mM. After agonist addition, Ca 2ϩ dynamics were recorded. Independent measurements of 10 M dopamine (100%) and unloaded (0%) cells were performed on each plate to normalize values from plate to plate. Concentration-response data were analyzed by using PRISM (GraphPad), and the corresponding EC 50 values were derived from single-curve fits. FLIPR studies were conducted in human, rat, and ferret D 4 receptors. Cloning of the ferret D 4 receptor in our laboratory revealed that the ferret D 4 receptor has 74% and 67% amino acid sequence identities to the rat D 4 and human D 4.4 receptors, respectively.
Methods
Conscious Rat Model of Penile Erection. Male adult Wistar rats (Ϸ300 g of body weight, obtained from Charles River Breeding Laboratories) were used as animal models to study penile erection in vivo as reported (18) . All animals were housed in American Association for the Accreditation of Laboratory Animal Care-approved facilities at Abbott Laboratories in a temperature-regulated environment under a controlled 12-h light-dark cycle, with lights on at 6:00 a.m. Food and water were available ad libitum except during testing. All testing was done following procedures outlined in protocols approved by Abbott's Institutional Animal Care and Use Committee. The experiments were carried out between 9:00 a.m. and 3:00 p.m. On the day of testing, animals were allowed to adapt to a diffusely illuminated testing room with red light for 1 h before the start of the experiment. Rats were placed individually into a transparent Plexiglas cage (20 ϫ 30 ϫ 30 cm) immediately after the drug injection. A mirror was placed behind and under the observation cages to facilitate observation of the animals. Each rat was used only once. A penile erection was considered to occur when the following behaviors were presented: repeated pelvic thrusts immediately followed by an upright position, and an emerging engorged penis that the rat proceeded to groom.
ABT-724 (maleate salt) was freshly prepared and administered to rats via s.c. injection into the back neck area (1 ml͞kg injection volume). For intracerebroventricular (ICV) or intrathecal administrations, rats were allowed at least 1 week of recovery from surgery before behavioral testing. The compounds of interest were infused ICV (left lateral ventricle) in a 5-l volume or 10 l intrathecally. After the experiment was completed, infusion of 0.5% fast-green dye in saline solution and subsequent dissection were carried out to confirm the diffusion of the injection solution.
Repeated dosing experiments were also conducted in the rat conscious penile erection model. For these studies, rats were dosed with either vehicle or ABT-724 (0.03 mol͞kg s.c.) once daily for 5 days. Animals were tested in the morning on day 1 and day 5 immediately after drug injection. To characterize the in vivo effect of sildenafil in combination with ABT-724 in conscious rats, sildenafil (1 mol͞kg, i.p.) was injected 30 min before ABT-724 s.c., and the rats were observed for 60 min for the occurrence of erections.
Penile erection episodes were recorded by direct observation for a period of 60 min after compound dosing, and erection incidence (%) was defined as the percent of animals exhibiting one or more erections during the observation period. Data were expressed as incidence (%) Ϯ SE. SE was calculated by the Wald equation, and the statistical evaluation of the data was performed by the 2 test. The number of penile erections was also counted and the data expressed as mean Ϯ SEM. These data were analyzed by the Mann-Whitney nonparametric U test.
Intracavernosal Pressure Registration in Conscious Rats. Sixteen male Sprague-Dawley rats (350-420 g) were anesthetized with pentobarbital and ketamine given by i.p. injection. Through a midline scrotal incision, the base of the penis was exposed. Using a 25-gauge needle, a small hole was made in the tunica albuginea of the crus cavernosum on one side and a heparinized (100 international equivalents per͞ml) PE50 polyethylene catheter was introduced. The catheter was secured by a 5͞0 pouch-suture in the fibrous tunica and by application of adhesive skin glue around the entrance hole. The scrotal skin was sutured and the catheter tunneled s.c. to the neck where it was anchored to the skin by 3͞0 sutures. Twelve hours after implantation of the catheter, the animals were placed in metabolic cages. Experiments were performed after a stabilizing period of 30 min. Continuous direct measurements of intracavernous pressure (ICP) were performed with P23 DC transducers and registered on a Grass Polygraph 7E (Grass Instruments, Quincy, MA). ABT-724 [1 g͞kg (0.0025 mol͞kg) or 10 g͞kg (0.025 mol͞kg)] or vehicle (saline) was then given by s.c. injection, and changes in ICP were registered during 60 min. Basal ICP, the total number of responses [Ͼ50 cmH 2 O (38 mmHg, 1 mmHg ϭ 133 Pa)], total duration of responses (the added duration of all responses Ͼ50 cmH 2 O or (38 mmHg)], time to first response, and peak ICP were analyzed in each rat. When appropriate, the results are given as mean values Ϯ SEM. One-way ANOVA was used for comparison between groups, followed by Bonferroni correction. All calculations are based on the number of individuals in the experiments.
Results and Discussion
The human D 4.4 receptor was cloned and stably expressed in HEK293 cells to determine the efficacy of the dopamine receptor agonists. Mouse, rat, and human D 4 receptors have been shown to couple via G i or G o to inhibit cAMP synthesis (19) (20) (21) (22) . However, coexpressing the D 4 receptor with chimeric G proteins (where the last five amino acids of G q are replaced by the last five amino acids of G o to generate G qo5 ) allows coupling to phospholipase C pathways (23) . In this way, activation of the D 4 receptor leads to changes in intracellular Ca 2ϩ levels. (Table 3) , whereas ABT-724 was inactive up to 10 M. Functional activity was determined in human D 2 receptors expressed in HEK293 cells with coexpression of the G protein chimera Gqo5. PNU-95666E and apomorphine were potent and efficacious D 2 receptor agonists, whereas ABT-724 did not activate human D 2 receptors in concentrations up to 10 M (Table 3) . Behavioral pharmacological studies were conducted in conscious Wistar rats to determine the effect of the D 4 receptor agonist on erectile function. This model was established in-house based on standard procedures used in several laboratories (24) . ABT-724 induced a significant facilitation of penile erection in rats after s.c. injections, as shown in Fig. 1 . A 77% maximal effect was observed at the 0.03 mol͞kg dose vs. 23% incidence in the control group. The latency to induce a penile erection in rats for ABT-724 was 18.7 min. Clozapine (10 mol͞kg, i.p.) and haloperidol (0.3 mol͞kg, i.p.), but not domperidone (10 mol͞kg, i.p.), blocked the erectogenic effect of ABT-724 in rats, indicating that the effect was mediated via central dopaminergic mechanisms, because the peripheral dopaminergic antagonist domperidone did not block the proerectile effect of ABT-724. A separate study was conducted to determine whether the proerectile effect of ABT-724 is maintained after five daily dosings. There was no tolerance to the proerectile effect of ABT-724 at 0.03 mol͞kg, because the incidence of penile erections in conscious rats was 71 Ϯ 12% on day 1 and 78 Ϯ 11% on day 5. The maximal concentration of ABT-724 at the 0.03 mol͞kg dose reached 5 min after drug administration was 5.0 ng͞ml (17 nM), a concentration comparable to the concentration Dopamine-induced increases in intracellular Ca ϩϩ were measured by fluorometric imaging plate reader. Data represent the mean Ϯ SEM EC 50 (nM) and efficacy (%) to increase intracellular Ca ϩϩ levels in comparison to dopamine 10 M (n ϭ 4 -18). In the binding studies, data represent the mean Ϯ SEM (n ϭ 4) using [ 125 I]-PIPAT as ligand. Functional data are represented as the mean Ϯ SEM EC50 and % efficacy (n ϭ 4) to increase intracellular calcium levels in comparison to dopamine 10 M (n ϭ 4).
Fig. 1.
Proerectile effect of ABT-724 in conscious Wistar rats after s.c. administration. Penile erection was assessed during a 60-min period after the injection of ABT-724. Data are expressed as erection incidence (%) Ϯ SE (n ϭ 30 rats per group). * , P Ͻ 0.05; ** , P Ͻ 0.01; *** , P Ͻ 0.001 vs. the vehicle group ( 2 test).
needed to activate the D 4 receptor. ABT-724 rapidly crossed the blood-brain barrier in rats and reached concentrations of 4.9 ng͞g of brain tissue 15 min after s.c. injection.
To determine the site of action of ABT-724 and to compare the effect of ABT-724 vs. apomorphine, a group of rats with chronically implanted cannulas were injected with these drugs directly into the lateral ventricle. A dose-response study was conducted with ABT-724 in comparison to the best dose of apomorphine based on previous studies (16) . Fig. 2 shows that nanomolar amounts of ABT-724 significantly facilitated erectile responses in conscious rats. The incidence and number of erections during the 60-min observation period were similar between ABT-724 (3 nmol) and apomorphine (3 nmol). The onset of action was also similar between these two groups (23.1 Ϯ 4.0 and 15.3 Ϯ 2.6 min, respectively). On the contrary, ABT-724 had no proerectile effect when injected intrathecally at the spinal level of L4-L6 in rats at doses of 3, 10, and 30 nmol. A modest effect was observed at the 100-nmol dose (50 Ϯ 14% incidence vs. 9 Ϯ 7% incidence in the vehicle-injected group), a dose 30-fold higher than the dose that induced a maximal effect after ICV injections.
To investigate whether ABT-724 would affect the cavernosal smooth muscle directly, a series of experiments was conducted in rabbit corpus cavernosum smooth muscle strips precontracted with phenylephrine. ABT-724 had no effect in concentrations up to 10 M, whereas sildenafil induced a complete relaxation with an EC 50 ϭ 44.37 Ϯ 11.2 nM (see supporting information). Apomorphine was also inactive in this assay in concentrations up to 10 M, consistent with previous data in the literature using rat cavernosal strips (25) . The effect of ABT-724 in combination with the PDE5 inhibitor sildenafil was also investigated in rats. Fig. 4 demonstrates that sildenafil (1 mol͞kg, i.p.) did not induce a significant effect at this dose in comparison to the vehicle group, and that ABT-724 by itself induced a maximal effect at the 0.03 mol͞kg dose. However, in the presence of sildenafil, a 10-fold potentiation of the incidence of erections was observed as ABT-724 reached a maximal effect at the 0.003 mol͞kg dose. These data suggest that the combination of a centrally acting agent with a peripherally acting agent might be beneficial for the treatment of patients suffering from ED.
Nonselective dopaminergic agents like quinpirole, 7-hydroxy-2-(di-n-propylamino)tetralin, quinelorane, and apomorphine exhibit affinity for D 2 , D 3 , and D 4 receptors and are known to induce nausea͞emesis. ABT-724 was evaluated in conscious male ferrets, a preclinical model to determine the emetic potential of drugs. ABT-724 was administered s.c. at 0.03, 0.3, and 3 mol͞kg. The number of emetic episodes and the presence of stereotypical behaviors that correlate with the sensation of nausea in ferrets were recorded during 90 min. ABT-724 did not cause emesis or nauseogenic behavior at any of the doses tested (Table 4) , despite its ability to activate ferret D 4 receptors. The highest dose tested is 100-fold greater than the maximally efficacious dose in the rat model of penile erection. The plasma levels reached in ferrets after the s.c. administration of 3 mol͞kg was 812 Ϯ 74 ng͞ml. Because the plasma level required for maximal efficacy in rats is 5 ng͞ml, the apparent tolerability index for ABT-724 is Ͼ160-fold. On the contrary, apomorphine induced emesis at the 0.3 mol͞kg dose in ferrets (2.3 Ϯ 0.4 episodes with a 10.5 Ϯ 2.6 min latency). The selective dopamine D 2 agonist PNU-95666E was identified from the literature (26, 27) and when tested in the ferret model PNU-95666E induced emesis after systemic injections of 1 and 3 mol͞kg ( Table 4 ). The emetic effect of PNU-95666E was completely blocked by the dopaminergic antagonist haloperidol (0.1 mol͞kg, s.c.). These data indicate that the activation of dopamine D 2 receptors is involved in the regulation of emetic responses, whereas the dopamine D 4 receptor does not play a role in emesis.
Expression of D 4 receptor mRNA has been reported in peripheral tissues including the atrium and ganglia (28, 29) . Although mRNA expression is limited, the effect of ABT-724 on cardiovascular and regional hemodynamic functions was assessed in rats to determine the peripheral actions of ABT-724. i.v. administration of ABT-724 in anesthetized Sprague-Dawley rats produced no significant effects on mean arterial pressure (MAP), heart rate, dP͞dt, or regional blood flow to renal, mesenteric, and hindquarter beds. Fig. 5 shows that ABT-724 was devoid of any effects on MAP, whereas a significant hypotensive effect is induced in this model by the adrenergic antagonist prazosin. A plasma concentration of 277 Ϯ 37 ng͞ml was achieved at the end of the high-dose infusion (3 mol͞kg) of ABT-724, a concentration 55-fold greater than the efficacious plasma level (5 ng͞ml) in the rat model of penile erection. Prazosin also significantly decreased hindquarter vascular resistance in rats, whereas ABT-724 did not affect this parameter. These data indicate that D 1 and D 2 , but not D 4 , receptors can significantly affect hemodynamic parameters in mammals (30, 31) .
The effect of ABT-724 on CNS behaviors was investigated to rule out potential stimulatory or propsychotic effects due to D 4 receptor stimulation. s.c. injections of ABT-724 (0.003-1.0 mol͞kg) did not affect locomotion of Wistar rats in the open field during a 20-min observation period. The doses tested in this study were 30-fold higher than the effective dose in rats (0.03 mol͞kg), and there was no indication of a stimulatory effect on locomotion. Amphetamine injections (1-3 mol͞kg, s.c.) significantly increased locomotion in rats. The prepulse inhibition (PPI) model in male Sprague-Dawley rats is used as a model to determine the potential antipsychotic properties of drugs. Amphetamine, a propsychotic agent in humans, disrupted the PPI response in rats (8.2 mol͞kg, s.c.), and this effect was blocked by haloperidol and clozapine. However, ABT-724 (0.03-1.0 mol͞kg, s.c.) neither blocked nor increased the PPI response. The Irwin test (32) was performed to determine the effects of ABT-724 on behavior, neurological symptoms, and rectal temperature in CD-1 mice. ABT-724 (0.1-100 mol͞kg, i.p.) did not induce observable effects up to 10 mol͞kg. The lowest dose of ABT-724 determined to cause behavioral side effects in mice was 100 mol͞kg, which produced only mild hypoactivity and ptosis (see supporting information). Methylphenidate was used as a positive control and induced clear signs of CNS stimulation, including hyperlocomotion, aggression, and convulsions. These CNSmediated behaviors were not induced by ABT-724, indicating that activation of the D 4 receptor does not lead to CNS stimulation, as observed for methylphenidate and amphetamine. Data are expressed as the percentage of ferrets exhibiting emesis, the mean Ϯ SEM number of emetic episodes, and the mean Ϯ SEM latency to vomit in minutes. Six ferrets were included in each group. These preclinical data demonstrate that the selective D 4 agonist ABT-724 can facilitate penile erection in conscious rats at doses devoid of cardiovascular, emetic, or CNS side effects. The proerectile effect of ABT-724 can be detected in a visual observation model in conscious rats and also by the increase in intracavernosal pressure responses in conscious rats.
There is extensive evidence in the literature demonstrating that pharmacological agents like apomorphine can facilitate penile erection by direct action in central areas of the nervous system (33), in contrast to sildenafil, which acts at the level of the cavernosal smooth muscle. Our data show that ABT-724 facilitates penile erection in rats after systemic and ICV administration. The effect of low doses of ABT-724 injected ICV in the rat, together with the lack of effect at the spinal level, its inability to relax corpus cavernosum strips, and lack of effect on different vascular beds provide further pharmacological support to the notion that the proerectile effect of ABT-724 is mediated by supraspinal dopaminergic mechanisms.
Although several publications have suggested that the erectogenic effect of nonselective dopamine receptor agonists like apomorphine is related to its activity at the D 2 receptor, our preclinical studies did not confirm this hypothesis (16) and indicate that the D 2 receptor agonist PNU-95666E induces modest nonsignificant effects on penile erection in rats, whereas it induces emesis in ferrets. Thus, activation of D 2 and D 4 receptors leads to a differential pharmacological profile, and the D 4 receptor plays a unique role in the control of penile erection. Because apomorphine is a potent D 2 agonist, the activation of D 2 receptors may be responsible for the higher incidence of nausea at higher doses that limits its clinical efficacy in ED patients. The use of a selective D4 agonist like ABT-724 that does not induce nausea will allow the use of a larger dose range to determine the maximal efficacy in ED patients.
ED affects a large population of men and can be classified based on severity, etiology, and onset of the disease. Based on the severity of ED, patients can be stratified as mild, moderate, or severe, depending on their ability to achieve and maintain an erection (34) . Although sildenafil is generally an efficacious agent for the treatment of ED, this drug has limited efficacy in a subpopulation of ED patients, e.g., diabetics. A PDE5 inhibitor cannot increase cGMP levels by itself unless there is release of NO that activates guanylate cyclase to increase cGMP levels (35) . In this situation, PDE5 inhibitors can maintain cGMP levels by blocking the metabolism of cGMP. The reduced efficacy of PDE5 inhibitors like sildenafil in diabetic patients may be due to the impaired neuronal and endothelium-dependent mechanisms (36) (37) (38) . Centrally acting agents may be able to enhance the signal that stimulates NO release from the nerve terminal, a critical process to increase cGMP levels in the smooth muscle. Either by itself or in combination with a PDE5 inhibitor, ABT-724 could achieve greater efficacy in diabetic patients.
During the past decade, the D 4 receptor has received significant attention in the psychiatric field due to the therapeutic effect of clozapine in psychotic patients that do not respond to classical dopamine receptor antagonists like haloperidol. Clozapine is a preferential antagonist of the dopamine D 4 receptor (11), and several potent D 4 antagonists were discovered aiming to improve the therapeutic efficacy of the antipsychotic agents (19, 39) . However, the D 4 hypothesis has not been confirmed in the clinic as the mechanism of action of antipsychotic agents (40, 41) . Other hypotheses regarding the physiological or pathophysiological role of the D 4 receptor have been based on knock-out animals (42, 43) or genetic association studies suggesting a potential role in noveltyseeking behavior, alcoholism, attention deficit, and depression; however, neither clinical nor preclinical research has confirmed these hypotheses (29) .
The dopamine D 4 receptor is expressed in various brain areas, and in situ hybridization as well as autoradiographic studies have demonstrated that the D 4 receptor is most abundant in the prefrontal cortex, hippocampus, amygdala, and hypothalamus (17) . In view of the preclinical evidence on the effect of apomorphine at the level of the periventricular nucleus of the hypothalamus to facilitate penile erection (33) and the proerectile effect of the selective D 4 receptor agonist ABT-724, the D 4 receptor expressed in the hypothalamus merits further investigation in relation to the control of penile erection and sexual function.
Conclusion
ABT-724 is a previously undescribed and selective dopamine D 4 receptor agonist that facilitates penile erection in rats at doses devoid of cardiovascular, emetic, or CNS side effects. The present preclinical studies demonstrate that dopamine D 4 receptors are involved in the regulation of penile function in mammals. The availability of a highly selective dopamine D 4 receptor agonist like ABT-724 will facilitate validation of this hypothesis in humans.
